ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet12980ometendo-13000Research ArticleЛЕКЦИЯLECTUREГипогонадизм и висцеральное ожирение у мужчин — полноправные компоненты метаболического синдромаHypogonadism and visceral obesity in men are full–fledged components of the metabolic syndromehttps://orcid.org/0000-0002-8520-8702ТрошинаЕ. А.TroshinaE. A.

Трошина Екатерина Анатольевна, доктор медицинских наук, член-корреспондент РАН, профессор

Москва

 

Ekaterina A. Troshina, MD, PhD, Professor

Moscow

 

troshina@inbox.ruhttps://orcid.org/0000-0003-3492-8344ТереховП. А.TerekhovР. A.

Терехов Петр Александрович

Москва

 

Petr A. Terekhov

Moscow

 

peterekhov@gmail.comНациональный медицинский исследовательский центр эндокринологииРоссияNational Medical Research Center of EndocrinologyRussian FederationМосковский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation2023230520232018491Copyright © Трошина Е.А., Терехов П.А., 20232023Трошина Е.А., Терехов П.А.Troshina E.A., Terekhov Р.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/13000

Гипогонадизм у мужчин может служить причиной развития ожирения, в первую очередь абдоминального, сопряженного с высокими кардиометаболическими рисками. Хроническое ожирение практически неизбежно ведет к манифестации гипогонадизма, требующего лечения и отягощающего сердечно-сосудистые риски. Терапия тестостероном, назначенная по показаниям, оказывает существенное положительное влияние не только на сексуальную функцию мужчины, но и на массу тела, углеводный и липидный обмен, костный метаболизм и эмоциональную составляющую мужского здоровья. Улучшение многих метаболических параметров у мужчин с верифицированным гипогонадизмом происходит на фоне достаточно длительной терапии тестостероном. Гипогонадизм и висцеральное ожирение сегодня рассматриваются в качестве компонентов метаболического синдрома, взаимно отягощают друг друга и требуют комплексного терапевтического подхода.

Hypogonadism in men can cause the development of obesity, primarily abdominal, associated with high cardio-metabolic risks. Chronic obesity, in turn, almost inevitably leads to the manifestation of hypogonadism, which requires treatment and aggravates cardiovascular risks. Testosterone therapy, prescribed according to indications, has a significant positive effect not only on a man’s sexual function, but also on body weight, carbohydrate and lipid metabolism, bone metabolism and the emotional component of men’s health. The improvement of many metabolic parameters in men with verified hypogonadism occurs against the background of fairly long-term testosterone therapy. Hypogonadism and visceral obesity are now considered as components of the metabolic syndrome, mutually burden each other and require a comprehensive therapeutic approach.

гипогонадизможирениеабдоминальное ожирениеметаболический синдромтестостеронкардиометаболический рискhypogonadismobesityabdominal obesitymetabolic syndrometestosteronecardio-metabolic riskСтатья подготовлена в рамках Го- сударственного задания N 122012100180-0 «Механизмы дезадаптации двухуровневой системы регуляции аппетита при экзогенно-конститу- циональном ожирении с множественными осложнениями и способы ее коррекции» (2022–2024 гг.)ReferencesPasquali R. Obesity and androgens: facts and perspectives. Fertil Steril. 2006;85(5):1319-1340. doi: https://doi.org/10.1016/j.fertnstert.2005.10.054Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril. 2006;85(5):1319-1340. doi: https://doi.org/10.1016/j.fertnstert.2005.10.054Трошина Е.А., Покусаева В.Н., Андреева Е.Н., и др. Ожирение у женщин / Под ред. Г.А. Мельниченко, Н.К. Никифоровского. — М.: ООО «Издательство «Медицинское информационное агентство»; 2017. — 272 с.Troshina EA, Pokusaeva VN, Andreeva EN, et al. Ozhirenie u zhenshhin. Ed by Mel’nichenko GA, Nikiforovskogo NK. Moscow: OOO «Izdatel’stvo «Medicinskoe informacionnoe agentstvo»; 2017. — 272 p. (In Russ.).Malkin CJ, Pugh PJ, Jones TH, Channer KS. Testosterone for secondary prevention in men with ischaemic heart disease? QJM. 2003;96(7):521-529. doi: https://doi.org/10.1093/qjmed/hcg086Malkin CJ, Pugh PJ, Jones TH, Channer KS. Testosterone for secondary prevention in men with ischaemic heart disease? QJM. 2003;96(7):521-529. doi: https://doi.org/10.1093/qjmed/hcg086Zumoff B, Strain GW, Miller LK, et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990;71(4):929-931. doi: https://doi.org/10.1210/jcem-71-4-929Zumoff B, Strain GW, Miller LK, et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990;71(4):929-931. doi: https://doi.org/10.1210/jcem-71-4-929Роживанов Р.В., Бобков Д.Н., Курбатов Д.Г. Патогенетические факторы патозооспермии и нарушения антиоксидантной активности эякулята у молодых мужчин с постпубертатным висцеральным ожирением и неотягощенным андрологическим анамнезом // Ожирение и метаболизм. — 2019. — Т. 16. — №3. — С. 76-80. doi: https://doi.org/10.14341/omet10054Rozhivanov RV, Bobkov DN, Kurbatov DG. Pathogenetic factors of disorders in spermatogenesis and antioxidative activity of an ejaculate in young men with post pubertal visceral obesity and normal andrological anamnesis. Obesity and metabolism. 2019;16(3):76-80. (In Russ.). doi: https://doi.org/10.14341/omet10054Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab. 1993;76(5):1140-1146. doi: https://doi.org/10.1210/jcem.76.5.8496304Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab. 1993;76(5):1140-1146. doi: https://doi.org/10.1210/jcem.76.5.8496304Corona G, Rastrelli G, Di Pasquale G, et al. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018;15(9):1260-1271. doi: https://doi.org/10.1016/j.jsxm.2018.06.012Corona G, Rastrelli G, Di Pasquale G, et al. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018;15(9):1260-1271. doi: https://doi.org/10.1016/j.jsxm.2018.06.012Longcope C, Kato T, Horton R. Conversion of blood androgens to estrogens in normal adult men and women. J Clin Invest. 1969;48(12):2191-2201. doi: https://doi.org/10.1172/JCI106185Longcope C, Kato T, Horton R. Conversion of blood androgens to estrogens in normal adult men and women. J Clin Invest. 1969;48(12):2191-2201. doi: https://doi.org/10.1172/JCI106185Pasquali R, Vicennati V. The abdominal obesity phenotype and insulin resistance are associated with abnormalities of the hypothalamic-pituitary-adrenal axis in humans. Horm Metab Res. 2000;32(11-12):521-525. doi: https://doi.org/10.1055/s-2007-978680Pasquali R, Vicennati V. The abdominal obesity phenotype and insulin resistance are associated with abnormalities of the hypothalamic-pituitary-adrenal axis in humans. Horm Metab Res. 2000;32(11-12):521-525. doi: https://doi.org/10.1055/s-2007-978680Bjorntorp P. Centralization of body fat P. In: International textbook of obesity. Chichester (UK): John Wiley & Sons; 2001. P. 213-224.Bjorntorp P. Centralization of body fat P. In: International textbook of obesity. Chichester (UK): John Wiley & Sons; 2001. P. 213-224.Rosmond R, Bouchard C, Björntorp P. Allelic variants in the GABA(A)alpha6 receptor subunit gene (GABRA6) is associated with abdominal obesity and cortisol secretion. Int J Obes Relat Metab Disord. 2002 Jul;26(7):938-41. doi: https://doi.org/10.1038/sj.ijo.0802022. PMID: 12080446.Rosmond R, Bouchard C, Björntorp P. Allelic variants in the GABA(A)alpha6 receptor subunit gene (GABRA6) is associated with abdominal obesity and cortisol secretion. Int J Obes Relat Metab Disord. 2002 Jul;26(7):938-41. doi: https://doi.org/10.1038/sj.ijo.0802022. PMID: 12080446.Rebuffé-Scrive M, Lundholm K, Björntorp P. Glucocorticoid hormone binding to human adipose tissue. Eur J Clin Invest. 1985;15(5):267-271. doi: https://doi.org/10.1111/j.1365-2362.1985.tb00182.xRebuffé-Scrive M, Lundholm K, Björntorp P. Glucocorticoid hormone binding to human adipose tissue. Eur J Clin Invest. 1985;15(5):267-271. doi: https://doi.org/10.1111/j.1365-2362.1985.tb00182.xHouseknecht KL, Mantzoros CS, Kuliawat R, et al. Evidence for leptin binding to proteins in serum of rodents and humans: modulation with obesity. Diabetes. 1996;45(11):1638-1643. doi: https://doi.org/10.2337/diab.45.11.1638Houseknecht KL, Mantzoros CS, Kuliawat R, et al. Evidence for leptin binding to proteins in serum of rodents and humans: modulation with obesity. Diabetes. 1996;45(11):1638-1643. doi: https://doi.org/10.2337/diab.45.11.1638Sahu A. Minireview: A hypothalamic role in energy balance with special emphasis on leptin. Endocrinology. 2004;145(6):2613-2620. doi: https://doi.org/10.1210/en.2004-0032Sahu A. Minireview: A hypothalamic role in energy balance with special emphasis on leptin. Endocrinology. 2004;145(6):2613-2620. doi: https://doi.org/10.1210/en.2004-0032Vettor R, De Pergola G, Pagano C, et al. Gender differences in serum leptin in obese people: relationships with testosterone, body fat distribution and insulin sensitivity. Eur J Clin Invest. 1997;27(12):1016-1024. doi: https://doi.org/10.1046/j.1365-2362.1997.2270773.xVettor R, De Pergola G, Pagano C, et al. Gender differences in serum leptin in obese people: relationships with testosterone, body fat distribution and insulin sensitivity. Eur J Clin Invest. 1997;27(12):1016-1024. doi: https://doi.org/10.1046/j.1365-2362.1997.2270773.xWabitsch M, Blum WF, Muche R, et al. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. J Clin Invest. 1997;100(4):808-813. doi: https://doi.org/10.1172/JCI119595Wabitsch M, Blum WF, Muche R, et al. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. J Clin Invest. 1997;100(4):808-813. doi: https://doi.org/10.1172/JCI119595Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90(5):2636-2641. doi: https://doi.org/10.1210/jc.2004-2190Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90(5):2636-2641. doi: https://doi.org/10.1210/jc.2004-2190Tschöp M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50(4):707-709. doi: https://doi.org/10.2337/diabetes.50.4.707Tschöp M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50(4):707-709. doi: https://doi.org/10.2337/diabetes.50.4.707Pagotto U, Gambineri A, Pelusi C, et al. Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab. 2003;88(9):4139-4143. doi: https://doi.org/10.1210/jc.2003-030554Pagotto U, Gambineri A, Pelusi C, et al. Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab. 2003;88(9):4139-4143. doi: https://doi.org/10.1210/jc.2003-030554Cryer A. Tissue lipoprotein lipase activity and its action in lipoprotein metabolism. Int J Biochem. 1981;13(5):525-541. doi: https://doi.org/10.1016/0020-711x(81)90177-4Cryer A. Tissue lipoprotein lipase activity and its action in lipoprotein metabolism. Int J Biochem. 1981;13(5):525-541. doi: https://doi.org/10.1016/0020-711x(81)90177-4Mårin P, Odén B, Björntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab. 1995;80(1):239-243. doi: https://doi.org/10.1210/jcem.80.1.7829619Mårin P, Odén B, Björntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab. 1995;80(1):239-243. doi: https://doi.org/10.1210/jcem.80.1.7829619Rosmond R, Bouchard C, Björntorp P. Allelic variants in the GABA(A)alpha6 receptor subunit gene (GABRA6) is associated with abdominal obesity and cortisol secretion. Int J Obes Relat Metab Disord. 2002;26(7):938-941. doi: https://doi.org/10.1038/sj.ijo.0802022Rosmond R, Bouchard C, Björntorp P. Allelic variants in the GABA(A)alpha6 receptor subunit gene (GABRA6) is associated with abdominal obesity and cortisol secretion. Int J Obes Relat Metab Disord. 2002;26(7):938-941. doi: https://doi.org/10.1038/sj.ijo.0802022Corona G, Giagulli VA, Maseroli E, et al. Therapy of endocrine disease: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99-116. doi: https://doi.org/10.1530/EJE-15-0262Corona G, Giagulli VA, Maseroli E, et al. Therapy of endocrine disease: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99-116. doi: https://doi.org/10.1530/EJE-15-0262Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272-283. doi: https://doi.org/10.1111/j.1743-6109.2010.01991.xCorona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272-283. doi: https://doi.org/10.1111/j.1743-6109.2010.01991.xБолезни жировой ткани / Под ред. И.И. Дедова. — М.: ГЭОТАР-Медиа; 2020. — 224 c. doi: https://doi.org/10.33029/9704-5367-4-BOL-1-224Bolezni zhirovoj tkani. Ed. by Dedov II. Moscow: GEOTAR-Media; 2020. 224 p. (In Russ.). doi: https://doi.org/10.33029/9704-5367-4-BOL-1-224Alexandersen P, Christiansen C. The aging male: testosterone deficiency and testosterone replacement. An up-date. Atherosclerosis. 2004;173(2):157-169. doi: https://doi.org/10.1016/S0021-9150(03)00242-9Alexandersen P, Christiansen C. The aging male: testosterone deficiency and testosterone replacement. An up-date. Atherosclerosis. 2004;173(2):157-169. doi: https://doi.org/10.1016/S0021-9150(03)00242-9Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6(1):1-7. doi: https://doi.org/10.1080/tam.6.1.1.7Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6(1):1-7. doi: https://doi.org/10.1080/tam.6.1.1.7Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335-4343. doi: https://doi.org/10.1210/jc.2006-0401Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335-4343. doi: https://doi.org/10.1210/jc.2006-0401Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5-15. doi: https://doi.org/10.3109/13685538.2015.1004049Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5-15. doi: https://doi.org/10.3109/13685538.2015.1004049Российская ассоциация эндокринологов. Клинические рекомендации. Дефицит тестостерона (гипогонадизм) у мужчин с сахарным диабетом. М.; 2019. Доступно по: https://cr.rosminzdrav.ru. Ссылка активна на 11.05.2023.Rossijskaja associacija jendokrinologov. Klinicheskie rekomendacii. Deficit testosterona (gipogonadizm) u muzhchin s saharnym diabetom. Moscow; 2019. (In Russ.)]. Доступно по: https://cr.rosminzdrav.ru. Ссылка активна на 11.05.2023.Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559. [Erratum in: J Clin Endocrinol Metab. 2021;106(7):e2848] doi: https://doi.org/10.1210/jc.2009-2354Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559. [Erratum in: J Clin Endocrinol Metab. 2021;106(7):e2848] doi: https://doi.org/10.1210/jc.2009-2354Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008;159(5):507-514. doi: https://doi.org/10.1530/EJE-08-0601Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008;159(5):507-514. doi: https://doi.org/10.1530/EJE-08-0601Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev. 2012;8(2):131-143. doi: https://doi.org/10.2174/157339912799424573Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev. 2012;8(2):131-143. doi: https://doi.org/10.2174/157339912799424573Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050-2058. doi: https://doi.org/10.1210/jc.2011-2591Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050-2058. doi: https://doi.org/10.1210/jc.2011-2591Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005;63(4):381-394. doi: https://doi.org/10.1111/j.1365-2265.2005.02350.xIsidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005;63(4):381-394. doi: https://doi.org/10.1111/j.1365-2265.2005.02350.xBoloña ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):20-28. doi: https://doi.org/10.4065/82.1.20Boloña ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):20-28. doi: https://doi.org/10.4065/82.1.20Zarrouf FA, Artz S, Griffith J, et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009;15(4):289-305. doi: https://doi.org/10.1097/01.pra. et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272-283. doi: https://doi.org/10.1111/j.1743-6109.2010.01991.xZarrouf FA, Artz S, Griffith J, et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009;15(4):289-305. doi: https://doi.org/10.1097/01.pra. et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272-283. doi: https://doi.org/10.1111/j.1743-6109.2010.01991.xBehre HM, Tammela TLJ, Arver S, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 mo. Aging Male. 2012;15(4):198-207. doi: https://doi.org/10.3109/13685538.2012.699562Behre HM, Tammela TLJ, Arver S, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 mo. Aging Male. 2012;15(4):198-207. doi: https://doi.org/10.3109/13685538.2012.699562Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639-650. doi: https://doi.org/10.1210/jc.2009-1251Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639-650. doi: https://doi.org/10.1210/jc.2009-1251

The authors declare that there are no conflicts of interest present.